Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies. by Han, Namshik et al.
Han et al., Sci. Adv. 2021; 7 : eabh3032     30 June 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
1 of 14
C O R O N A V I R U S
Identification of SARS-CoV-2–induced pathways  
reveals drug repurposing strategies
Namshik Han1*†, Woochang Hwang1†, Konstantinos Tzelepis1†, Patrick Schmerer2†, 
Eliza Yankova1, Méabh MacMahon1,3, Winnie Lei1,4, Nicholas M. Katritsis1,5, Anika Liu1,6,7, 
Ulrike Felgenhauer2, Alison Schuldt1, Rebecca Harris1, Kathryn Chapman1, Frank McCaughan8, 
Friedemann Weber2, Tony Kouzarides1,9*
The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the rapid 
development of new therapies against coronavirus disease 2019 (COVID-19) infection. Here, we present the 
identification of 200 approved drugs, appropriate for repurposing against COVID-19. We constructed a SARS-CoV-2–
induced protein network, based on disease signatures defined by COVID-19 multiomics datasets, and cross- 
examined these pathways against approved drugs. This analysis identified 200 drugs predicted to target 
SARS-CoV-2–induced pathways, 40 of which are already in COVID-19 clinical trials, testifying to the validity of 
the approach. Using artificial neural network analysis, we classified these 200 drugs into nine distinct path-
ways, within two overarching mechanisms of action (MoAs): viral replication (126) and immune response (74). 
Two drugs (proguanil and sulfasalazine) implicated in viral replication were shown to inhibit replication in cell 
assays. This unbiased and validated analysis opens new avenues for the rapid repurposing of approved drugs into 
clinical trials.
INTRODUCTION
To date, most small-molecule and antibody approaches for treating 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–
related pathology are rightly rooted in repurposing and are focused 
on several key virus or host targets or on pathways as points for 
therapeutic intervention and treatment. This has been underpinned 
by the unprecedented pace of scientific research to uncover the mo-
lecular bases of virus structure and the mechanisms by which it 
gains access to cells before replication and release of new virus par-
ticles. The emergence of global proteomic datasets is now propel-
ling our understanding of the mechanisms through which the virus 
interacts with host cell proteins, determining the directly interact-
ing proteins (DIPs) (1) and differentially expressed proteins (DEPs) 
(2). Such interactome outputs and related efforts in transcriptomics 
(3) have begun to provide detailed information on possible individ-
ual targets and pathways against which currently available drugs 
can be tested for potential coronavirus disease 2019 (COVID-19) 
repurposing. Systematic analyses of these datasets will direct fur-
ther research toward likely points of successful therapeutic inter-
vention. In this study, we have applied the power of bespoke 
computational biology and machine learning approaches to dis-
sect these datasets and construct an agnostic network for SARS-
CoV-2–induced pathways, uncovering novel targets and potential 
repurposing strategies (Fig. 1A). We have focused our study on 
host-directed therapy, an emerging and complementary approach 
to virus-targeting drugs, that interferes with signaling mechanisms 
in the host cell to effectively inhibit the productivity of viral repli-
cation (4).
RESULTS
Construction of a SARS-CoV-2–induced protein network
To determine the disease mechanisms underlying a SARS-CoV-2 
infection, we undertook a comprehensive analysis of the protein 
pathways implicated in COVID-19, using computational biology 
workflows for data integration and network construction. To this 
end, we hypothesized that DIPs are the “cause” and DEPs are the 
“consequence” of SARS-CoV-2 infection. We then constructed a 
SARS-CoV-2–induced protein (SIP) network in which all DIP and 
DEP combinations are connected to understand how the chains of 
the cause and consequences are connected (Fig. 1B). We identified 
all the possible shortest paths between 332 DIP and 64 DEP combi-
nations in the SIP network at 6 hours and between 332 DIP and 
164 DEP combinations in the SIP network at 24 hours using the 
human STRING database (5). In our SIP network, there are three 
layers: the DIP, the DEP, and the hidden layer between the two. 
Our analysis of the DEP data identified DIPs at 6 and 24 hours 
after infection; hence, we constructed the SIP network for these 
two time points. There are 13,308 proteins and 344,543 interactions 
in the 6-hour network and 14,827 proteins and 528,969 interactions 
in the 24-hour network [fig. S1 shows the entire SIP network at 
the two time points; Fig. 1C shows a subnetwork of SARS-CoV-2 
Orf8 (Open reading frame 8) at 24 hours]. Almost 99% of the DIP-
to-DEP paths in both networks are via more than one protein 
(Fig. 1D), and there is only a 2% overlap between DIP and DEP. It 
suggests that the “hidden layer” that we have constructed in our 
network is central to understanding the pathways that connect DIPs 
and DEPs and allows us to discover novel relationships by integrat-
ing the datasets.
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The SIP network can be interrogated to reveal key proteins 
and disease pathways
In protein-protein interaction (PPI) networks, proteins that are 
central to a pathway are desirable as druggable targets because they 
may have a greater impact on pathway function. To identify key 
proteins and disease pathways in the SIP network, we applied mul-
tiple network algorithms [including eigenvector centrality, degree 
centrality, betweenness centrality, and random walk with restart 
(RWR)]. To identify statistically significant proteins, we performed 
1000 permutation tests for each network algorithm and selected 
proteins with empirical P values less than 0.01. The proteins selected 
by each network algorithm were merged and considered as key pro-
teins (see Materials and Methods). This revealed 320 proteins at 
6 hours and 394 proteins at 24 hours, of which 238 (50% of 476 
proteins) proteins were in common (Fig. 2A). More than half of the 
proteins identified as significant at both time points were in the hid-
den layer: 170 (53%) and 202 (51%), respectively (fig. S2, A and B). 
We then asked whether these proteins were also biologically rele-
vant to the disease symptoms caused by COVID-19. A disease 
enrichment analysis on the proteins showed that the top 10 en-
riched diseases for these proteins at both time points are diseases 
that are potentially relevant for COVID-19 pathogenesis, including 
lung disease (6, 7), hypertension (6, 7), and hyperglycemia (table S1) 
(6). To uncover potential biological functions of the important pro-
teins at 6 hours, 24 hours, and both time points, we tested for en-
richment of disease (8) and Gene Ontology (GO biological process) 
terms to characterize the key proteins in the SIP network. For pro-
teins at 6 hours and proteins that are common to both time points, 
the pathways were related to the immune system and virus replica-
tion (VR) (fig. S3, A and B). In contrast, the pathways that were 
relevant for the proteins at 24 hours were primarily related to VR 
(fig. S3C). In this way, we established a COVID-19 SIP network that 
allows investigation of disease pathways that are pertinent to SARS-
CoV-2 infection.
SARS-CoV-2 viral protein subnetwork analysis demonstrates 
an enrichment of pathways related to viral replication
SARS-CoV-2 has a large RNA viral genome (~30,000 nucleotides) 
with subgenomic structures that produce 29 viral proteins (4 struc-
tural proteins, 16 nonstructural proteins, and 9 accessory factors of 
the virus genome). To understand the disease mechanism of 
COVID-19, we investigated the subnetwork for each of these viral 
proteins and asked which biological processes these are implicated 




Fig. 1. Construction of a SIP network. (A) Overview and workflow of the in silico drug repurposing pipeline. (B) Schematic depicts our strategy of constructing a SIP 
hidden network through data integration and network construction of DIPs and DEPs, followed by identification of drugs that target key pathways in this network. (C) The 
SARS-CoV-2 Orf8 subnetwork shows the extent of the hidden layer that is revealed through the network analysis. (D) Percentage of the shortest paths between the DIP 
and DEP that are via zero to three proteins at 6 hours versus 24 hours.
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subnetwork: (i) the differences between the 6- and 24-hour time 
points (Fig. 2, B and C, and table S2); (ii) the subcellular localization 
of the key proteins (table S3); and (iii) the biological processes that 
the key proteins act in (table S4).
First, we found a significantly increased number of interactions 
with RNA metabolism at 24 hours (1504 interactions at 6 hours 
but 6794 at 24 hours with a P value of 2.2 × 10−16; Fig. 2D and 
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Fig. 2. SARS-CoV-2 viral protein subnetwork analysis shows an enrichment of viral replication pathways. (A) Venn diagram of key proteins in 6- and 24-hour SIP 
networks. (B) A circos plot depicting interactions between DIPs and DEPs revealed through the SIP network at 6 hours after infection. DIPs were subdivided into the 
genomic organization of SARS-CoV-2. Proteins in the hidden layer were also subdivided into major pathways. Inner colored circles demonstrate the subcellular localization 
of the proteins, and details are shown in the dotted box. The colored lines show PPI. (C) Twenty-four hours after infection. (D) Top 30 enriched GO terms of the key proteins 
in the SIP network at 24 hours (black). The enrichment P values of 30 terms at 6 hours are also shown as a control (gray).
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Nsp 8 (Nonstructural protein 8), and Orf8 and Orf10 of SARS-CoV-2 
interact with ribosomal proteins in the hidden layer of our SIP net-
work, indicating that they may have a possible influence on RNA 
metabolism (Fig. 2, B and C, and table S2). The N and Nsp 8 pro-
teins are known to drive viral replication (1). Orf8 and Orf10 are the 
only two proteins of SARS-CoV-2 that are distinct from other corona-
viruses (9). We also observed that Orf8-interacting DIPs were 
enriched in the endoplasmic reticulum (ER) (Fig. 2, B and C, and 
table S3), which may be significant as the ER is the intracellular 
niche for viral replication and assembly (10). Of the 28 proteins that 
SARS-CoV-2 Orf8 directly interacts with, 13 (46.43%, P value: 3.18 × 
10−6) are localized in the ER, compared with only 11.84% (36) of all 
other DIPs (304) being localized in ER.
We then sought the most relevant biological pathways—immune 
system and viral replication—that have previously been described 
for SARS-CoV-2 (11) at the highest hierarchical level in the Reac-
tome pathway database. The “immune system” (P value: 9.57 × 
10−18) (12) was identified for the immune response (IR). The 
“metabolism of RNA” (P value: 5.37 × 10−45) (12, 13) and “cell cycle” 
(P value: 1.73 × 10−16) (14) were found for viral replication. The key 
proteins belonging to these three pathways were assigned to the 
three subgroups (purple, metabolism of RNA; red, cell cycle; and 
light blue, immune system) under the hidden layer in Fig. 2 (B and 
C). The key proteins that did not belong to any of the three path-
ways were assigned to “others.” There were 54 key proteins in the 
hidden layer that did not have strong enrichment in the Reactome 
pathways (other) but that still actively interacted with metabolism 
of RNA proteins at 24 hours (Fig. 2C and tables S2 and S4). Further 
study on the other proteins found individual links to RNA binding 
(ATP5A1, MRTO4, and NHP2L1), host-virus interaction (ACE2, 
CXCR4, DERL1, GNB2L1, HSPD1, KDR, KRT18, SIRT1, and 
TMPRSS2), histones (H2AFZ, HIST2H3PS2, and WDTC1), viral 
mRNA translation (MRPS7), and ER-associated responses (ATF4, 
CFTR, DERL1, and INS).
We next confirmed statistically that virus-related pathways are 
enriched in the top 30 enriched GO terms (P value less than 4.64 × 
10−17) of 976 enriched GO terms (P value less than 0.05) as well as 
RNA- and ER-related processes (Fig. 2D; see fig. S4, A and B, for the 
top 150 terms and table S4 for all enriched GO terms). The differ-
ences between the two time points were also confirmed. In summary, 
our pattern analysis in the SARS-CoV-2 viral protein subnetworks 
revealed which biological pathways change significantly during the 
course of infection, with prominent increases in proteins involved 
in VR by 24 hours (Fig. 2D).
An in silico network proximity analysis of drug-target 
relationships identifies drug candidates
Having identified key SIP proteins, we were motivated to identify 
approved drugs that bound a significant number of these host pro-
teins and which might therefore have stronger effects in blocking 
SARS-CoV-2–induced changes. We conducted an in silico network- 
based proximity measure analysis (15) on the key proteins of the 
SIP network at 6 and 24 hours after infection. We collected 1917 
approved drugs from publicly available databases [ChEMBL (16) 
and DrugBank (17); table S5]. This virtual screening identified 200 
drugs (table S6) that are predicted to target the key proteins of the 
SIP network, of which 99 (49.5%) were specific to the 6-hour time 
point, 14 (7%) were specific to the 24-hour time point, and 87 
(43.5%) were common to both time points. We then checked the 
Anatomical Therapeutic Chemical code (available for 180 drugs 
only) to determine the therapeutic areas for which specific drugs 
have been developed. The top clinical areas against which these 
approved drugs are used for were cancer, sex hormone signaling, 
diabetes, immune system, bacterial disease, and inflammatory/
rheumatic disease (fig. S5). A total of 35% of the 200 drugs have 
been tested in phase 2 or 3 clinical trials for infectious diseases, and 
half of these were HIV trials; furthermore, 16% of drugs have been 
tested in trials for inflammatory and 10% in respiratory disease.
Among the 200 identified drugs, 40 (20%) are now in COVID-19 
clinical trials (tables S6 and S7) (18). To determine the significance 
of this finding, we asked what the likelihood would be of this num-
ber of drugs being identified as hits by chance. We found that, by 
comparison, only 13% of the approved drugs (249 of 1917) were in 
the COVID-19 clinical trials (18). A hypergeometric test for the 
probability of 20% of our 200 drugs being in clinical trials returned 
a P value of 3.59 × 10−3, demonstrating the utility of our integrated 
computational approaches for prioritizing compounds. Of the 200 
drugs identified, a further total of 30 drugs have also been reported 
as being potential candidates against COVID-19 (19–24). Thus, 
network-based proximity analysis has revealed 70 drugs in total that 
are either in COVID-19 clinical trials or being considered as poten-
tial drug candidates in preclinical studies, supporting the strength 
of our approach. In this way, our analysis has identified a total of 
130 drugs that could provide novel opportunities for repurposing as 
COVID-19 therapeutics. The full list of 200 approved drugs along 
with their detailed information is shown in table S6.
Artificial neural network analysis uncovers drug 
mechanisms of action
We next wanted to establish the mechanism of action (MoA) under-
lying the 200 identified drugs. In particular, we wanted to cluster 
the pathways and mechanisms to better evaluate their potential 
effect and utility. An initial pathway enrichment test performed on 
the proteins that are targeted by the 200 drugs identified a set of 
148 key pathways (see Materials and Methods). We then calculated 
the precision and recall of the enrichment test to produce an F1 
score that is the measure of the enrichment accuracy (see Materials 
and Methods). The F1 scores were calculated per drug-pathway 
association; in this way, we generated an F1 score matrix (for the 
200 drugs and 148 key pathways; table S8). To investigate the MoA 
(that is, the profile of pathways in which drug targets are signifi-
cantly enriched) for the 200 drugs in the context of COVID-19, we 
used a self-organizing map (SOM), a type of artificial neural net-
work, to analyze the relationship between the 200 drugs and the 148 
key pathways (termed as drug-pathway association).
First, to characterize each of the 148 key pathways, the unsuper-
vised training of SOM with the F1 score matrix generated 148 SOM 
component plane heatmaps (fig. S6). The SOM successfully predicted 
highly correlated pathways, although only the F1 scores and no prior 
biological knowledge of the 148 key pathway or the 200 drugs were 
used in the SOM training. Each heatmap represents the intensity 
patterns of a pathway, and each hexagon in the heatmap is a unique 
neuron or “node” of the SOM artificial neural network. To allow 
direct comparison between heatmaps (pathways), the hexagons 
(neurons) have the same position across all heatmaps. In this way, a 
group of pathways are correlated if their heatmaps are visually sim-
ilar. For instance, three heatmaps at the grid positions of A7, B7, 
and C7 in fig. S6 are visually similar. The three heatmaps represent 
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pathways for “G1-S transition,” “G2-M checkpoints,” and “G2-M 
transition”; thus, they are biologically correlated in cell cycle. To 
summarize the correlation of 148 heatmaps, the unified distance 
matrix (U-matrix) between the neighbor neurons was also calculated 
and presented in different colored hexagons, which illustrates the 
probability density distribution of data vectors (drug-pathway asso-
ciation score) (Fig. 3A) (25).
Next, the 148 key pathways were separated into nine clusters by 
a k-means clustering algorithm with Davies-Bouldin index (DBI). 
The nine clusters were “metabolism of lipids,” “metabolism of 
protein,” “DNA replication,” “G2 or M cell cycle,” “hemostasis,” 
“metabolic disorder,” “Toll-like receptor (TLR) or G protein– 
coupled receptor (GPCR) signaling,” “receptor tyrosine kinase (RTK) 
signaling,” and “cytokine signaling” (shown in different colors in 
Fig. 3B). To determine the optimal number of clusters, we calculated the 
DBI based on the U-matrix. The lowest DBI value occurs at nine clus-
ters (fig. S7); thus, we decided to separate the 148 key pathways into nine 
pathway clusters. The size of the black hexagon in each colored hexa-
gon indicates distance to its neighbor hexagon; thus, a larger black 
hexagon indicates more correlation with its neighbor hexagons.
The nine pathway clusters were then mapped into potentially 
important MoA categories for SARS-CoV-2 infection by pathway 
analysis (table S9). To identify these categories, we first searched the 
COVID-19–related literature and determined that there are mainly 
“two broad categories” of disease mechanism reported: (i) IR and 
(ii) viral replication (11). We then mapped the nine pathway clus-
ters based on two factors: (i) biological supporting evidence from 
the literature and (ii) computationally inferred evidence from SOM 
clustering arrangements. The detailed source of the biological sup-
porting evidence is shown in table S9. The computationally inferred 
evidence was provided by the SOM clustering arrangements be-
tween the nine pathway clusters (Fig. 3B). For instance, RTK signal-
ing is closely positioned by two hallmark immune system pathways 
(cytokine signaling and TLR/GPCR signaling) on the SOM cluster-
ing arrangements (Fig. 3B). Thus, RTK signaling was predicted to 
have a high probability of having a role in the IR. The mapping 
revealed two MoA categories that could explain the mechanisms of 
the 200 identified drugs. The two MoA categories were VR and IR 
(Fig. 3C). For instance, 47 pathways among the 148 key pathways 
are related to metabolism of lipids that plays a key role at various 
stages in viral replication, including entry, uncoating, genome 
replication, assembly, and release (26). There are 18 pathways related 
to DNA replication, and it is known that intermediate and late viral 
mRNAs concentrate in DNA replication factories (27). We also found 
seven cytokine signaling pathways that regulate the IR (28). The entire 
mapping results and supporting evidence are provided in table S9.
Last, the SOM mapped the 200 drugs into each neuron and 
hence the key pathways (the number of drugs per neuron is shown 
in Fig. 3D, and drug names are shown in Fig. 3E). Notably, 30 of the 
40 drugs that are in COVID-19 clinical trials (18) were in the VR 
MoA category, while only 10 drugs were in the IR (Fig. 3D). We 
then identified mechanistic roles and connections for the 200 drugs 
and their target proteins and mapped the drugs into nine pathway 
clusters (Fig. 3E). A more extensive analysis of information about 
each drug is given in table S6.
Proguanil and sulfasalazine reduce SARS-CoV-2 replication
We next sought to identify the precise proteins within the SIP net-
work that are targeted by each of the 200 drugs. We found that, of 
the 1573 proteins targeted by the 200 drugs, most (66%) are targeted 
by a single drug (fig. S8A). However, there are 30 proteins (0.19%) 
that are targeted by eight or more drugs (P value less than 0.00757; 
fig. S8A). To establish whether there is a pathway relationship 
between these 30 proteins, we interrogated their molecular function. 
Figure S8B shows that the most enriched categories of function for 
these proteins were heme, microsome, oxidoreductase, and mono-
oxygenase, all of which are related to nicotinamide adenine dinucle-
otide phosphate (NADP) and nitric oxide (NO) synthesis. As NO is 
important for viral synthesis (and because NADP affects NO pro-
duction), this could provide a potential mechanism by which these 
drugs might alter viral infection (29–31). On the basis of these find-
ings, we decided to validate, in cellular assays, five drugs (ademe-
tionine, alogliptin, flucytosine, proguanil, and sulfasalazine) with 
good safety profiles that are functioning within this pathway. Com-
pounds targeting the same pathway but with serious safety issues 
were not progressed for cellular validation.
To assess whether these five drugs are able to reduce SARS-CoV-2 
infection, we performed an initial screening using the monkey Vero 
E6 cell line, where we observed that two of the five drugs, namely 
proguanil and sulfasalazine, showed significant antiviral effects 
without any noticeable cellular toxicity at the indicated doses (Fig. 4A 
and fig. S9A). We then focused on these two drugs, expanding our 
validation using the human Calu-3 cell line (in addition to Vero E6 
cells). Treatment of Vero E6 and Calu-3 cells with proguanil and 
sulfasalazine illustrated strong anti–SARS-CoV-2 effects (repre-
sented by reductions of the envelope and nucleocapsid gene RNAs) 
in a dose-dependent manner, mirroring the results of the initial 
screen (Fig. 4, B to E, and fig. S9, B to E). No significant effect on 
cellular viability was observed at any tested dose (fig. S9, F to H). 
The effective concentration of sulfasalazine is comparable to maxi-
mal plasma concentrations achieved routinely in patients with 
rheumatoid arthritis or inflammatory bowel disease (32).
To further demonstrate the anti–SARS-CoV-2 impact of these 
two drugs, we examined the status of recently found intracellular 
pathways directly associated with SARS-CoV-2 infection and cyto-
kine production (33). Treatment with either proguanil or sulfasalazine 
significantly reduced the phosphorylation of MAPKAPK2 (p-MK2 
and T334) (Fig. 4F), an important component of the p38/mitogen- 
activated protein kinase (MAPK) signaling pathway, which has 
been shown to be activated via SARS-CoV-2 infection and stimulate 
cytokine response (33). Treatment of Calu-3 and Vero E6 cell lines 
with proguanil and sulfasalazine led to a significant down-regulation 
of the mRNA of key cytokines (Fig. 4, G to J, and fig. S10), which are 
dictated by the p38/MAPK signaling pathway and shown to become 
elevated during SARS-CoV-2 infection and replication (CXCL3, 
IFNB1, and TNF-A) (33). Hence, the above results solidify the 
promising anti–SARS-CoV-2 effects of the two drugs, both at the 
viral and the molecular level.
DISCUSSION
Here, we have used a series of computational approaches—including 
bespoke methods for data integration, network analysis, computer 
simulation, and machine learning—to identify novel SARS-CoV-2–
induced pathways that could be targeted therapeutically by repur-
posing existing and approved drugs (Fig.  1A). Although network 
analysis is increasingly being used for the analysis of genetic data-
sets to uncover disease signatures (34), a few key aspects of our 
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Fig. 3. Machine learning predicts MoAs for the 200 drug repurposing candidates. (A) U-matrix is shown of the trained unsupervised SOM used to analyze the rela-
tionship between the 200 drugs and the 148 key pathways. This contains the distance (similarity) between the neighboring SOM neurons (pathways) and shows data 
density (drug-pathway association scores) in input space. Each hexagon is colored according to distance between corresponding data vectors of neighbor neurons, with 
low-distance areas (dark purple) indicating high data density (clusters). Each smaller hexagon on the U-matrix (A) indicates the data vector distance between larger hexa-
gons in the SOM cluster arrangements (B to E). Thus, a smaller hexagon on the U-matrix corresponds to every adjacent larger hexagon on the SOM cluster arrangements 
(B to E). (B) The selected clustering arrangement was based on the U-matrix and DBI to separate the 148 key pathways into nine clusters. The names of nine clusters are 
shown in the figure. Clusters of each SOM neuron are distinguishable by color. The size of the black hexagon in each neuron indicates distance. Larger hexagons have a 
low distance to neighboring neurons, hence forming a stronger cluster with neighbors. (C) Two MoA categories were identified on the basis of the pathway clustering 
and the drug mapping. (D) Mapping of the 200 identified drugs to each neuron (pathway) based on matching rates and inspection of examples from each cluster. (E) SOM 
component map shows mapping results of the 200 drugs into nine pathway clusters. The names of the nine clusters are shown in the figure, and the drugs with asterisk 
are already in COVID-19 clinical trials.
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approach were essential in uncovering these new targets, including 
agnostic construction of the SIP network and application of novel 
algorithms (previously used in other industries including social 
media). In addition, the use of artificial neural networks to understand 
systematically the MoA for the drugs was vital to this investigation.
Our analysis identifies 200 approved drugs, along with their 
MoA, that may be effective against COVID-19 (table S6). We are 
confident that these drugs have a potential for repurposing for 
COVID-19, since 40 of the 200 drugs have already entered clinical 
trials, testifying to the discovery value of our approach. An important 
part of our analysis is the use of already approved drugs. This allows 
for the rapid advancement of the most promising of the 160 drugs 
that are not yet in clinical trials.
We identify two drugs, sulfasalazine and proguanil, that can 
reduce SARS-CoV-2 viral replication in cellular assays, raising the 
exciting possibility of their potential use in prophylaxis or treat-
ment against COVID-19. To understand why sulfasalazine and 
proguanil are effective against SARS-CoV-2 infection but others 
A B C
D E F
G H I J
Fig. 4. Proguanil and sulfasalazine reduce SARS-CoV-2 replication and p38/MAPK signaling activity. (A) RT-qPCR analysis of the indicated mRNA (envelope, E-protein) 
from Vero E6 cells pretreated with the indicated drugs and concentrations for 3 hours before infection with SARS-CoV-2 for 24 hours. Student’s t test. Means + SD of 
three independent replicates are shown. (B and C) RT-qPCR analysis of indicated mRNA (envelope, E-protein) from Vero E6 cells pretreated with proguanil or sulfasalazine 
at indicated concentrations for 3 hours before infection with SARS-CoV-2 for 24 hours. Student’s t test. Means + SD of three independent replicates are shown. (D and 
E) RT-qPCR analysis of indicated mRNA (envelope, E-protein) from Calu-3 cells pretreated with proguanil or sulfasalazine at indicated concentrations for 3 hours before 
infection with SARS-CoV-2 for 24 hours. Student’s t test. Means + SD of three independent replicates are shown. (F) Western blot analysis of phosphorylated MAPKAPK2 
(Thr334) in mock-, DMSO-, sulfasalazine-, or proguanil-treated Vero E6 cells at indicated concentrations for 3 hours before infection with SARS-CoV-2 for 24 hours. (G to J) 
RT-qPCR analysis of the indicated mRNAs from Calu-3 cells pretreated with proguanil or sulfasalazine at indicated concentrations for 3 hours before infection with SARS-
CoV-2 for 24 hours. Student’s t test. Means + SD of three independent replicates are shown.
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functioning in the same pathway were not (Fig. 4A), we looked 
more closely at the targets of each drug. Figure 5 shows that SARS-
CoV-2 Orf8 binds to -glutamyl hydrolase (GGH) and regulates the 
synthesis of NO, which is necessary for viral synthesis. An additional 
auxiliary pathway, mediating the synthesis of NADP, can also affect 
NO production, although indirectly. Sulfasalazine and proguanil 
impinge on both of these pathways: Sulfasalazine targets the NF-B 
inhibitors NFKBIA and IKBKB as well as CYP450 enzymes, whereas 
proguanil targets DHFR and CYP450 enzymes plus interacting 
partners (table S6). In this way, we hypothesize that these two drugs 
might more effectively target NO production and thus disrupt viral 
replication. By contrast, the three drugs that were not effective 
against SARS-CoV-2 infection (flucytosine, alogliptin, and ademe-
tionine) only affect one of the two pathways. This analysis thereby 
highlights the possibility that targeting NO production through 
multiple pathways may provide a potential rationale for the efficacy 
of sulfasalazine and proguanil in reducing viral replication.
Safety is a particularly important consideration, since such drugs 
could be prescribed to any COVID-19–positive individuals who 
may have a broader range of underlying medical conditions and 
may not be hospitalized at the time of taking the drug. Sulfasalazine 
and proguanil have the potential to be used prophylactically or 
therapeutically. Both drugs are well-established and well-tolerated 
drugs (35, 36). Sulfasalazine is already in use as an anti-inflammatory 
drug against autoimmune disorders. Given that this drug has anti-
viral activity (Fig.  4), this raises the possibility that sulfasalazine 
may act not only as an antiviral but also as an anti-inflammatory if 
used against COVID-19. Proguanil is used against malaria in com-
bination with atovaquone. It has an excellent safety profile and is 
well tolerated when used as a prophylactic and in treatment (37).
A complementary study using large-scale compound screening 
in cultured cells has recently uncovered 100 molecules that have a 
partial effect on viral infectivity, 21 of which show a dose-dependent 
reduction of viral replication (38). This list of drugs does not over-
lap with ours, with only 2 of our 200 approved drugs being present 
in this list (and neither sulfasalazine nor proguanil being among 
them). The main reason for this apparent disparity is that only 10% 
of the 100 compounds tested by Riva et  al. (38) are approved, 
whereas 100% of our 200 drugs are approved. Eight drugs in the 
study by Riva et al. (38) that were approved by the U.S. Food and 
Drug Administration (FDA) are acitretin, astemizole (now with-
drawn), chloroquine, clofazimine, ingenol mebutate, remdesivir, 
tazarotene, and tretinoin. Two others are approved only in China 
(flumatinib mesylate) or Japan (tamibarotene). This highlights the 
major difference in the two studies: Our in silico studies identify 
potential antiviral drugs that are already approved and therefore at 
an advanced stage of repurposing, whereas Riva et al. (38) have 
identified compounds validated in African green monkey cells 
VeroE6, most of which are either in preclinical or phase 1 to 3 clin-
ical trials. Gordon et al. (1) introduced 69 drugs (29 of which are 
approved by the FDA, 12 of which are in clinical trials, and 28 of 
which are preclinical compounds) that bound DIP. Among the 29 
approved drugs, 9 drugs (captopril, chloroquine, daunorubicin, 
indomethacin, loratadine, lovastatin, metformin, mycophenolic acid, 
and sirolimus) overlap with our 200 identified drugs, and 8 of these 
are currently in clinical trials for SARS-CoV-2.
Computational studies aiming to identify candidate drugs for 
COVID-19 drug repurposing have used multistage analyses includ-
ing network proximity measure analysis that are focused on DIP 
specifically and its interactomes (39–41). By contrast, our strategy 
Fig. 5. Schematics depicting the pathways mediating NO production that are targeted by the five tested drugs. The black boxes indicate key proteins in SIP net-
work, and those targeted by the five drugs are highlighted in red color. Sulfasalazine and proguanil target proteins in both pathways that directly and indirectly (via NADP 
production) affect NO production (58–61).
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has been to holistically construct the entire pathway of proteins that 
are significantly affected during SARS-CoV-2 infection, through 
uncovering of the hidden layer between the DIP and DEP. Because 
the DIP and DEP were identified from two recent papers (1, 2) that 
generated proteomic data in two different cell lines (DIP in human 
embryonic kidney 293 cells and DEP in Caco-2), we also used four 
different network algorithms to systematically identify the key pro-
teins (see Materials and Methods). Furthermore, our approach not 
only identified the 200 drugs but also used neural network analy-
sis to predict the MoA of the drugs. This combination of unique 
approaches allowed us to short-list drugs associated with VR, 
which were then experimentally tested in monkey cell VeroE6 
and human Calu-3 cells. However, similar to other network anal-
ysis studies, PPI networks usually lack the directionality that pro-
vides additional information about the types of interaction (i.e., 
activation or inhibition). It will be beneficial to analyze additional 
data that provide insights into this directionality (i.e., CRISPRi 
datasets showing patterns of up-/down-regulation) to overcome 
this limitation.
Our study has shed unanticipated new light on COVID-19 dis-
ease mechanisms and has generated promising drug repurposing 
opportunities for prophylaxis and treatment. Our data-driven 
unsupervised approach and biological validation have uncovered 
160 approved drugs not currently in clinical trials, which can be 
investigated immediately for repurposing, and 2 drugs that show 
promise as antiviral drugs. We expect that this resource of potential 
drugs will facilitate and accelerate the development of therapeutics 
against COVID-19. Furthermore, our bespoke data-driven compu-
tational approach should be useful for a rapid response to new vari-
ants of SARS-CoV-2 and other new pathogens that could drive 
future pandemics and will also be applicable to other noninfectious 
disease areas with high unmet medical need.
MATERIALS AND METHODS
Directly interacting proteins and differentially 
expressed proteins
A total of 332 high-confidence SARS-CoV-2–human interactions 
were obtained from Gordon et al. (1) (table S3 from https://doi.
org/10.1038/s41586-020-2286-9). A total of 332 high-confidence 
virus-host interactions were used as DIP. Data of proteome mea-
surements by mass spectrometry at 6 and 24 hours after SARS-CoV-2 
infection were obtained from Bojkova et  al. (2) (table S2 from 
https://doi.org/10.1038/s41586-020-2332-7). The proteins that were sig-
nificantly up- or down-regulated (two-sided, unpaired Student’s t test 
with equal variance assumed, P < 0.05, |log2FC| > 0.5) were selected.
SIP network construction
The SIP network was constructed of all the shortest paths between 
DIP and DEP in a human PPI network from the STRING database 
(v11.0) (5). The main purpose of constructing the SIP network in 
our study was to identify COVID-19 disease–associated proteins. 
The STRING database was selected as the PPI database given the 
previous evidence that it contains more comprehensive informa-
tion on diverse collections of disease-associated protein sets com-
pared with other databases (42).
Only interactions with a confidence score of more than medium 
(0.4) were used. The 0.4 cutoff is the default setting and the medium 
level of confidence for PPI searches in the STRING database 
(43, 44). This study used network algorithms to identify key 
proteins by investigating the whole network. Thus, the cutoff was 
used to construct a more comprehensive network that captures any 
potential interactions, and then the network analysis was conducted 
to systematically identify key proteins by analyzing all these possi-
ble interactions. The STRING database does not provide directional 
information.
All of the shortest paths between all pair proteins of DIP and 
DEP on the human PPI network were found using Dijkstra algo-
rithm. For the shortest path finding, we used the Python package 
NetworkX (v2.2) (45). Networks were visualized using Gephi 0.9.2 
(fig. S1) (46).
Network analysis
Eigenvector centrality, degree centrality, betweenness centrality, 
and RWR were used to identify key proteins in SIP networks. The 
SIP network is represented by an adjacency matrix A, where Aij = 1 
if there is an edge between nodes i and j or Aij = 0 otherwise. The 
eigenvector centrality xi was defined as
  x = xA (1)
where x is an eigenvector of the adjacency matrix A with eigenvalue . 
If  is the largest eigenvalue of the adjacency matrix A, there is a 
unique solution x, and all centrality values are positive (47). Degree 
centrality of node i was defined as
  C D (i ) =  ∑ 
j=1
N
  A ij (2)
where N is the number of nodes in the SIP network. Betweenness 
centrality of a node i was defined as
  C B (i ) =  ∑ 
s,t∈V
  (s, t ∣ i)  ─ 
(s, t)  (3)
where V is the set of nodes, (s, t) is the total number of shortest 
paths between s and t, and (s, t∣i) is the number of number of the 
shortest paths between s and t paths passing through node i. If s = t, 
(s, t) = 1, and if i ∈ s, t, (s, t∣i) = 0.
Eigenvector centrality was used to identify the most influential 
proteins in the network. If a protein is frequently interacted by other 
proteins, which also have high eigenvector centrality, then the pro-
tein will have high eigenvector centrality. Degree centrality was 
used to identify the hub proteins in the network. Betweenness cen-
trality was used to identify the bottleneck proteins in the network. 
The betweenness centrality algorithm finds the number of the 
shortest paths that pass through the given protein among all protein 
pairs in the SIP network. RWR was used to see which human pro-
teins were affected the most upon SARS-CoV-2 infection. To do 
this, we used 332 DIPs as the starting points of RWR. The RWR 
parameters were (i) a restart probability that is 0.15, (ii) a maximum 
iteration number that is 100, and (iii) an error tolerance of 1 × 10−6. 
We have assigned edge betweenness centrality as an edge score on 
the SIP network. The RWR calculated a score per protein in the SIP 
network that indicates how much a given protein was influenced by 
SARS-CoV-2 via DIP. The algorithms were implemented in the 
Python package NetworkX (v2.2) (45).
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Permutation tests were performed 1000 times to identify signifi-
cant proteins for each of the network centrality algorithms. In 1000 
permutation tests, each test generated a random network with a 
preserved degree distribution of the original network, the SIP net-
work. To generate a random network, we reconnected the edge in 
the SIP network and swiped the node. The random network in each 
permutation test therefore has at least 66% of the rewired edges. In 
the permutation test, we then applied the network algorithm and 
obtained the cumulative results of the network algorithm. These cu-
mulative results were used to calculate the empirical P value of the 
network algorithm. We combined the four permutation test results 
to determine the final set of key proteins that have an empirical 
P value of ≤0.01 in either result.
Key protein functional enrichment analysis
Key proteins of SIP network were tested for enrichment of DISEASES 
(8) and GO (GO biological process) terms. Enrichment analyses 
were performed using REST API of Enrichr (https://maayanlab.
cloud/Enrichr/) (48).
Visualization of a key network of SIP network
Key networks were built using interactions between the key pro-
teins of the SIP network at 6 and 24 hours after infection. When 
visualizing the key networks, subcellular localization of key proteins 
and enriched pathways of hidden layer proteins was added (Fig. 2, 
B and C). Subcellular localization information for key proteins was 
found using COMPARTMENT database (49). Among the available 
datasets in the COMPARTMENT database, “knowledge channel” 
data with a confidence score of greater than four was used. The 
knowledge channel for humans is based on the annotations of 
UniProtKB, manually curated data. The confidence score of four is 
the highest confidence score of the knowledge channel and is only 
applicable to data with experimental results. To identify enriched 
functions of the hidden layer proteins, the hidden layer proteins 
were tested for enrichment of Reactome pathway terms. Most hidden 
layer proteins belonged to the pathways metabolism of RNA, cell 
cycle, and immune system, so we subdivided the hidden layer pro-
teins into three subgroups for key network visualization. The visu-
alization was carried out using Circos (50).
Drug-target interactions
Approved drugs were collected from ChEMBL (16) and DrugBank 
(17). Drug-target interaction information was collected from Drug-
Bank (v5.1) (17), STITCH (v5.0, confidence score > 0.9) (51), and 
Cheng et al. (52).
In silico network-based proximity analysis
In silico network-based proximity analysis was conducted for key 
proteins from the SIP network at 6 and 24 hours. Given K, the set of 
key proteins from SIP networks, and T, the set of drug targets, the 
network proximity(Eq. 4) of K with the target set of T of each ap-
proved drug where d(k, t), the shortest path length between nodes k 
∈ K and t ∈ T in the human PPIs (52), was executed. The closest 
distance measure was used to calculate the distance between a given 
drug’s targets to our key proteins in the SIP network because it 
showed the best performance in drug-disease pair prediction in the 
study of Guney et al. (15)
  d c (K, T ) =  1 ─ ‖T‖  ∑ t∈T mi  n k∈K d(k, t) (4)
To assess the significance of the distance between a key protein 
of SIP network and a drug dc(K, T), the distance was converted to z 
score based on permutation tests by using
   z(K, T ) =  
d(K, T ) −  d(K,T)   ─  d(K,T)  (5)
The permutation tests were repeated 1000 times, each time with 
two randomly selected gene sets. There are few high-degree nodes 
due to the scale-free network of the human PPI network. To avoid 
repetitive selection of the same high-degree nodes during random 
selection, we used a binning approach with at least 100 nodes in a 
bin. In the binning approach, nodes in the same bin have similar 
node degree to maintain node degree distribution for random selec-
tion. When we randomly select a set of genes, we performed a ran-
dom selection among proteins from all bins so that the minimum 
node degree was less than the minimum node degree of the selected 
gene set and the maximum node degree was greater than the maxi-
mum node degree of the selected gene set. The corresponding P 
value was calculated on the basis of the permutation test results. 
Drug–to–SARS-CoV-2 associations with a z score of less than −2 
were considered significantly proximal (15).
Drug-pathway associations
To understand the MoAs for our 200 identified drugs, we conducted 
the Reactome pathway enrichment analysis for the target proteins 
of these drugs using R (v3.5.2) package, gprofiler2 (hypergeometric 
test, P value of <0.05) (53). Reactome pathway database (the version 
as of 15 May 2020) was used for pathway enrichment analysis because 
it is the most actively updated public database of human pathways (54). 
Pathway enrichment analysis was first performed using only the target 
proteins of each of the 200 drugs. However, 120 of 200 drugs did not 
have significantly enriched pathways because these drugs had fewer 
than six target proteins. To overcome this issue, “one-degree” neighbor 
proteins were added for those drugs targeting fewer than six proteins.
Significantly enriched biological pathways of drug targets for 
each of the 200 drugs were integrated, resulting in 148 key path-
ways. The Reactome pathway has a hierarchical structure among 
pathways. The lower hierarchy pathway is more specific than the 
higher hierarchy pathway. The parent pathway semantically in-
cludes the children pathways. In the process of integrating the en-
riched pathways per drug, we used the lowest possible hierarchy 
pathways to avoid the overlapping biological meaning among the 
hierarchical pathways.
On the basis of these identifications, a matrix containing F1 
scores of the 200 drugs and the 148 key pathways was generated for 
drug-pathway association. The Reactome pathway enrichment analy-
sis for the 200 drugs using gprofiler2 provides enrichment P values 
and precision and recall information that were used to produce the 
F1 scores. The meaning of precision here is the proportion of drug 
targets that are annotated to the pathway. The meaning of recall 
here is the proportion of the pathway gene set that the drug targets 
recover. The pathway to which the largest number of drug target 
proteins belong has the highest precision value. The pathway with 
the greatest intersection of pathway proteins and target proteins has 
the highest recall value. In other words, the pathway with the high-
est F1 score in the drug-pathway associations is the pathway to 
which the drug’s target protein belongs the most and the pathway 
with the largest intersection between the target proteins. For example, 
the number of target proteins for sulfasalazine is 13. The number of 
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“arachidonic acid metabolism” pathway proteins is 59. The number 
of intersections between the target protein of sulfasalazine and the 
arachidonic acid metabolism pathway protein is 4. So, the precision 
is 4/13 = 0.3077, and the recall value is 4/59 = 0.0678. Thus, the F1 
score is 0.1111. The number of “fatty acid metabolism” pathway 
proteins is 177, and the number of intersections between the target 
protein of sulfasalazine and the fatty acid metabolism pathway pro-
tein is 4. The precision is the same as 0.3077 for arachidonic acid 
metabolism, but the recall value is 4/177 = 0.0225. Thus, the F1 
score is 0.0421, which is lower than the arachidonic acid metabo-
lism. Hence, the F1 score complements the imbalance between the 
pathway protein and the target protein. This matrix was constructed 
using the F1 score [F1 = 2(precision × recall)/(precision + recall)] 
from the pathway enrichment analysis (table S8).
MoA analysis
We used SOM (55) to cluster pathways based on their protein com-
ponents and F1 score profiles. SOM has a descriptive ability and 
hence advantages in visual concept detection. Thus, it was useful to 
directly compare the SOM component heatmaps of the 148 path-
ways. SOM also has the advantage of dimensional reduction to al-
low a more appropriate clustering result. SOM was used followed 
by k-means clustering to calculate the low-dimensional abstractions 
that are then clustered using k-means. This two-phase approach in-
creases the efficiency of k-means clustering with a relatively small 
number of samples that is a limitation in hierarchical clustering algo-
rithms. Another advantage of SOM is noise reduction because SOM 
abstractions are less sensitive to random variations than the input 
data. In addition, SOM offers a systematic arrangement of the 200 drugs 
to each neuron and hence to pathway clusters (Fig. 3, D and E).
The data used in training was the F1 score matrix for drug- 
pathway associations (148 pathways by 200 drugs; table S8). From the 
SOM training, we generated a U-matix that represents the distance 
between neighboring nodes in the map. U-matrix of the trained un-
supervised SOM contains the vector norms between the neighbor-
ing SOM nodes and shows data density in input space. Each subunit 
is colored according to distance between corresponding data vec-
tors of neighbor units. Low-distance areas (dark blue) have high 
data density (clusters) (Fig. 3A). DBI (56) was calculated on the ba-
sis of the U-matrix to determine the optimal number of clusters. We 
used the DBI, a metric for within-cluster distance at various SOM 
parameters. Minimizing this index allowed discovery of groups of 
pathways with shared MoA or protein overlaps. The lowest DBI 
value occurred at nine clusters, and thus, we decided to separate the 
148 key pathways into nine pathway clusters (fig. S7). K-means 
algorithm was then used to find the nine pathway clusters (Fig. 3B). 
The SOM component maps of 148 pathways (fig. S6) were analyzed 
on the basis of the clustering result (Fig. 3B) and mapped into two 
MoA categories based on the biological functions (Fig. 3C). The 
mapping result of 148 pathways to nine clusters and two MoA groups 
is available in table S9. The SOM model also labeled each neuron 
with the 200 drugs (Fig. 3, D and E). The detailed information of the 
labeled SOM neurons and the 200 drugs is available in table S6 
(columns V and W). The SOM Toolbox package (57) for MATLAB 
was used for this analysis with default settings and parameters.
Quantification of the most frequently targeted proteins 
among the 200 drugs
The frequency of drug-protein targeting was counted. Permutation 
tests were then performed 100 times to identify the significance 
threshold for the frequency of drug-protein targeting (fig. S8A). For 
each permutation test, the 200 drugs among all the drugs that we 
used for the in silico network-based proximity analysis were ran-
domly selected. Then, the number of drugs targeting the same pro-
tein was calculated for all of the randomly selected 200 drugs. The 
proteins frequently targeted in the SIP network (empirical P value 
of <0.01) were then tested for enrichment of UniProt keywords (fig. 
S8B). Since UniProt keyword contains a mixture of information 
from 10 different categories, it was used for the enrichment test to 
detect any mechanistic differences among the 200 drugs.
Cell culture
Chlorocebus sabaeus (green monkey) Vero E6 cells [Vero 76, clone 
E6, Vero E6, American Type Culture Collection (ATCC) CRL-1586] 
authenticated by ATCC and tested negative for mycoplasma con-
tamination before commencement were maintained in a humidified 
atmosphere at 37°C with 5% CO2, in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS; 
Invitrogen). Calu-3 (ATCC HTB-55) human lung cells that tested 
negative for mycoplasma contamination before commencement were 
maintained in a humidified atmosphere at 37°C with 5% CO2 in 
Eagle’s minimum essential medium containing 20% (v/v) FBS. Human 
cell lines used were either not listed in the cross-contaminated or 
misidentified cell line database curated by the International Cell Line 
Authentication Committee or were previously verified by karyotyping.
Viruses and infections
Infection experiments were performed under biosafety level 3 con-
ditions. SARS-CoV-2 (strain München-1.2/2020/984) isolate was 
propagated in Vero E6 cells in DMEM supplemented with 2% FBS. For 
Table 1. Gene names and primer sequences used in the study.  
RT-PCR
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infection experiments in Vero E6 and Calu-3 cells, SARS-CoV-2 (strain 
München-1.2/2020/984) viral supernatant was used at multiplicity 
of infection (MOI) = 0.01 plaque-forming units per cell for 24 hours. 
All work involving live SARS-CoV-2 was performed at the BSL-3 
facility of the Institute for Virology, University of Giessen (Germany), 
and was approved according to the German Act of Genetic Engineer-
ing by the local authority.
Cell infection and drug treatment
Vero E6 and Calu-3 cells were seeded using 8 × 104 cells in 24-well plates. 
The following day, cells were treated for 3 hours before infection with 
the indicated doses of ademetionine (30 M; Selleckchem), alogliptin 
(10 M; Selleckchem), flucytosine (300 M; Selleckchem), proguanil 
(5 nM to 500 M; Selleckchem), sulfasalazine (5 nM to 500 M; 
Selleckchem), IFN-A (1000 U/ml), dimethyl sulfoxide (DMSO; Sigma- 
Aldrich), or mock and infected with SARS-CoV-2 at an MOI of 0.01 in 
serum-free DMEM at 37°C for 24 hours before RNA or protein lysis. 
Infection experiments were performed under biosafety level 3 conditions.
Quantitative RT-PCR analysis
RNA was isolated using the RNeasy Mini Kit (Qiagen). SARS-CoV-2 
replication (E-gene and N-gene RNA) and gene expression of the 
cytokines CXCL3, IFNB1, and TNF-A were quantified by reverse 
transcription quantitative polymerase chain reaction (RT-qPCR). For 
complementary DNA (cDNA) synthesis, RNA was reverse-transcribed 
with the SuperScript VILO cDNA Synthesis Kit (Invitrogen, 11755-050). 
The levels of specific RNAs were measured using the ABI 7900 re-
al-time PCR machine and the PowerUp SYBR Green Master Mix 
(Applied Biosystems, 100029284) according to the manufacturer’s 
instructions. CT values were determined relative to glyceraldehyde- 
3-phosphate dehydrogenase (GAPDH), and CT values were 
normalized to infected DMSO-treated samples. Error bars indicate 
the SD of the mean from three independent biological replicates. All 
primer sequences are listed in Table 1 below.
Cytotoxicity cell viability assays
Cytotoxicity was performed in Vero E6 and Calu-3 cells using Neutral 
Red (Abcam, ab234039) and [3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide (MTT)] (Roche) assay, respectively, 
according to the manufacturer’s instructions. Cytotoxicity was per-
formed in Vero E6 and Calu-3 cells with the indicated compound 
dilutions and concurrent with viral replication assays. All assays 
were performed in biologically independent triplicates.
Western blot analysis
A total of 8 × 104 Vero E6 cells either mock-infected or infected and 
treated with DMSO or proguanil (50 M) or sulfasalazine (200 M) 
for 24 hours were resuspended and lysed in whole-cell 1× SDS sam-
ple buffer [4× SDS sample buffer: 143 mM tris-HCl (pH 6.8), 28.6% 
glycerol, 5.7% SDS, and 4.3 mM bromophenol blue]; supplemented 
with 2 ml of 2-mercaptoethanol, protease inhibitors (Sigma-Aldrich), 
and phosphatase inhibitors (Sigma-Aldrich); and boiled for 5 min 
at 95°C. A total of 10 to 20 g of protein were separated on 
SDS–polyacrylamide gel electrophoresis gels and blotted onto 
polyvinylidene difluoride membranes (Millipore).
Antibodies
Western blot experiments were performed using the following anti-
bodies: GAPDH (Abcam, ab9484), phospho-MAPKAPK2 (Thr334, 
Cell Signaling Technology, 3007), goat anti-rabbit (Abcam, ab6721), 
and anti-mouse horseradish peroxidase (Cell Signaling Technolo-
gy, 7076S).
Statistical analysis
Statistical analyses performed are specified in the figure legends. 
Differences were considered significant for P values of <0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/27/eabh3032/DC1
View/request a protocol for this paper from Bio-protocol.
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